NCT01389479View on ClinicalTrials.gov

Study to Evaluate the Safety, Tolerance and Immunogenicity of Fluviral™ in Healthy Adults

PHASE3CompletedINTERVENTIONAL
Enrollment

1,000

Participants

Timeline

Start Date

January 31, 2005

Primary Completion Date

May 31, 2005

Study Completion Date

May 31, 2005

Conditions
Influenza
Interventions
BIOLOGICAL

Fluviral™

Intramuscular, single dose

BIOLOGICAL

Fluzone®

Intramuscular, single dose

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
collaborator

ID Biomedical Corporation, Quebec

INDUSTRY

lead

GlaxoSmithKline

INDUSTRY

NCT01389479 - Study to Evaluate the Safety, Tolerance and Immunogenicity of Fluviral™ in Healthy Adults | Biotech Hunter | Biotech Hunter